
The Serum Institute of India, renowned for its pivotal role in global immunization efforts, is poised to significantly enhance the supply of its human papillomavirus (HPV) vaccine. With plans to offer the vaccine at reduced rates for a government-backed immunization campaign against the cancer-causing virus, the institute is set to make a substantial impact on public health initiatives. Adar Poonawalla, the CEO of Serum Institute, outlined the institute’s commitment to expanding HPV...